Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)
14 Junho 2019 - 8:00AM
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announces
today that senior management will be presenting in the upcoming
JMP Life Sciences Conference in New York City.
Sorrento Therapeutics
Speaker: Dr. Henry
Ji (Chairman and CEO)
Date/Time: June
20th, 2019 at 11:30 AM
Location: The St.
Regis New York, New York
Webcast:
http://investors.sorrentotherapeutics.com/events-and-presentations/events
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to turn
malignant cancers into manageable and possibly curable diseases.
Sorrento's multimodal multipronged approach to fighting cancer is
made possible by its extensive immuno-oncology platforms, including
key assets such as fully human antibodies (“G-MAB™ library”),
clinical stage immuno-cellular therapies (“CAR-T”), intracellular
targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”),
and clinical stage oncolytic virus (“Sephrevir®”).
Sorrento's commitment to life-enhancing therapies for cancer
patients is also demonstrated by our effort to advance a
first-in-class (TRPV1 agonist) non-opioid pain management small
molecule in Resiniferatoxin (“RTX”) and ZTlido™. Resiniferatoxin is
completing a phase IB trial in terminal cancer patients. ZTlido was
approved by US FDA on 02/28/18.
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc., under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include statements regarding the expectations for
Sorrento's and its subsidiaries' technologies and product
candidates. Risks and uncertainties that could cause our
actual results to differ materially and adversely from those
expressed in our forward-looking statements, include, but are not
limited to: risks related to Sorrento's and its subsidiaries'
technologies and prospects, including Sorrento’s anti-CD38 and
anti-BCMA cell therapy and CAR and CAR-T programs and drug
products; risks related to seeking regulatory approvals and
conducting clinical trials; and other risks that are described in
Sorrento's most recent periodic reports filed with the Securities
and Exchange Commission, including Sorrento's Annual Report on Form
10-K for the year ended December 31, 2018, and subsequent Quarterly
Reports on Form 10-Q filed with the Securities and Exchange
Commission, including the risk factors set forth in those filings.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release and we undertake no obligation to update any
forward-looking statement in this press release except as required
by law.
Media and Investor Relations
Contact: Alexis Nahama
Telephone: 1.858.203.4120
Email: mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of
Sorrento Therapeutics, Inc.
ZTlido™ and G-MAB™ are trademarks owned by Scilex
Pharmaceuticals, Inc. and Sorrento, respectively.
Seprehvir®, is a registered trademark of Virttu Biologics
Limited, a wholly-owned subsidiary of TNK Therapeutics, Inc. and
part of the group of companies owned by Sorrento Therapeutics,
Inc.
All other trademarks are the property of their respective
owners.
© 2019 Sorrento Therapeutics, Inc. All Rights
Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024